Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V(1A) and V2 receptor antagonist

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 357, Issue 1, 1997, Pages 63-69

  Tahara, A ^a   Saito, M ^a   Sugimoto, T ^a   Tomura, Y ^a   Wada, K ^a   Kusayama, T ^a   Tsukada, J ^a   Ishii, N ^a   Yatsu, T ^a   Uchida, W ^a   Tanaka, A ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Nonpeptide antagonist; Second messenger systems; Vasopressin; Vasopressin V(1A) receptor; Vasopressin V2 receptor

Indexed keywords

ARGIPRESSIN; CALCIUM ION; CONIVAPTAN; NEW DRUG; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL STRAIN COS1; DISSOCIATION CONSTANT; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR DENSITY; SCATCHARD PLOT;

EID: 15444339098     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005139     Document Type: Article

References (30)

1. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W (1992) Molecular cloning of the receptor for human antidiuretic hormone. Nature 357: 333-335
2. Bouby N, Bachmann S, Bichet D, Bankir L (1990) Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258: F973-F979
3. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108
4. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T (1993) Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 44: 19-23
5. Goldsmith SR, Francis GS, Cowley AW Jr, Goldenberg IF, Cohn JN (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8: 779-783
6. 1 renal epithelial cells at physiological temperature. EMBO J 8: 2481-2488
7. Kim JK, Michel JB, Soubrier F, Durr J, Corvol P, Schrier RW (1990) Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int 38: 818-822
8. Kinter LB (1991) Antidiuretic hormone antagonism in humans: are there predictors? In: Jard S, Jamison R (eds.) Vasopressin. John Libbey Eurotext. Paris, pp. 321-329
9. Kruszynski M, Lammek B, Manning M, Seto J, Haldar J, Sawyer WH (1980) [1-(beta-Mercapto-beta,beta-cyclopentamethyl-enepropionic acid), 2-(O-methyl) tyrosine]arginine-vasopressin and [1-(beta-Mercapto-beta,beta-cyclopenta-methyl-enepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J Med Chem 23: 364-368
10. Laszlo FA, Laszlo F Jr, De Wied D (1991) Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43: 73-108
11. Manning M, Sawyer WH (1986) Synthesis and receptor specificities of vasopressin antagonists. J Cardiovasc Pharmacol 8 [Suppl 7]: S29-S35
12. 1-receptor) responses to vasopressin. J Med Chem 33: 3079-3086
13. 6 interchange in nonselective and selective vasopressin and oxytocin antagonists. J Med Chem 38: 1762-1769
14. Michell RH, Kirk CJ, Billah MM (1979) Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 7: 861-865
15. Mizushima S, Nagata S (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18: 5322
16. Mulinari RA, Gavras I, Wang YX, Franco R, Gavras H (1990) Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation 81: 308-311
17. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T (1994) Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dous. Am. J Physiol 267: H2245-H2254
18. Nicod P, Waeber B, Bussien JP, Goy JJ, Turini G, Nussberger J, Hofbauer KG, Brunner HR (1985) Acute hemodynamic effect of vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 55: 1043-1047
19. Pettibone DJ, Kishel TM, Woyden CJ, Clineschmidt BV, Bock MG, Freidinger RM, Veber DF, Williams PD (1992) Radioligand binding studies reveal marked species differences in the vasopressin V receptor of rat, rhesus and human tissues. Life Sci 50: 1953-1958
20. 1a receptors. J Clin Invest 92: 224-231
21. 2 receptor antagonist. J Clin Invest 98: 2729-2738
22. 1h vasopressin receptor. J Biol Chem 269: 27088-27092
23. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305: 263-266
24. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282: 301-308
25. Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K, Yoshida M, Arai N (1988) SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 8: 466-472
26. 1a vasopressin receptor. J Biol Chem 269, 3304-3310
27. Tovey KC, Oldham KG, Whelan JA (1974) A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. Clin Chim Acta 56: 221-234
28. Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y (1991) OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252: 572-574
29. 2 receptor antagonist. Br J Pharmacol 105: 787-791
30. 1A and V; receptor antagonist, in dogs. Eur J Pharmacol 321: 225-230